leisure time -WSS

leisure time

author：hotspot 2025-10-03 19:57:23 - browse：34

The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Brain 'hot spot' may explain why African Americans feel greater pain

WSS

How medical schools plan to diversify without affirmative action

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Long Covid needs a new name — and a new frame

RaDonda Vaught case: a double standard for nurses, physicians

What to make of Biden’s latest efforts on cancer research

Pig kidney works a record two months in donated body

Wikipedia

leisure time

entertainment

At least 13 dead in Texas as scorching temps continue

Bacterial infection may be ‘key event’ in endometriosis, study says

Sports medicine is finally prioritizing gender equality

Listen: Biogen's messy board & Laronde's data problem

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Sports medicine is finally prioritizing gender equality

4th of July breaks record for highest global temperature ever measured

Cancer drug shortages should be causing more outrage

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

entertainment

Acelyrin, a rare IPO success, stumbles in its first big test

New Covid vaccine is recommended for everyone 6 months or older

FDA panel endorses Alnylam’s heart drug — after picking it apart

Regeneron agrees to White House price limits on anti

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

New weight loss drugs vying to be the next Wegovy or Mounjaro

hotspot

explore

focus

Wikipedia